Sir, Cerebral venous sinus thrombosis (CVT) accounts for 0.5%-1% of all stroke cases. [1] Stroke registry in India reported 1.22% of strokes to be due to CVT. It is commonly seen in young female in peripartum period. [2] The etiological factors include pregnancy, dehydration, use of oral contraceptive pills or other drugs, infections, prothrombotic states, hematological disorders, and connective tissue disorders. [1] Most common clinical features are headache and seizures. [3, 4] Diplopia, papilledema, and motor deficits such as mono or hemiparesis are frequent findings.
[1] Systemic anticoagulation using conventional or low molecular weight heparin is the mainstay of treatment.
[1] About 9%-13% of patients deteriorate on anticoagulation and direct catheter-guided thrombolysis or mechanical thrombectomy is preferred treatment modality in such cases. [1, 5] A 25-year-old postpartum female and a 35-year-old female on treatment for polycystic ovarian disease, presented with recent onset headache followed by left hemiparesis. Second patient also had generalized tonic-clonic seizure. Both had superior sagittal sinus (SSS) thrombosis and were worsening on heparin, clinically as well as on imaging. As patients were worsening on anticoagulation, endovascular intervention was considered. After femoral venous access, 7F guiding catheter was negotiated into right internal jugular vein. Diagnostic venous angiogram confirmed venous sinus occlusion, 6F distal access catheter (DAC) catheter was negotiated into the sinus, maceration of clot was done with the same catheter and with to-and-fro movements of 035 Terumo wire followed by aspiration of clot. Postprocedure angiogram showed good recanalization of SSS in both [ Figure 1a -d].
Both the patients had significant clinical improvement over the next 2-3 days and modified Rankin Scale at 3 months is 1.
We report two cases where emergent restoration of sinus patency was done with the use of DAC catheter only. In the process, we avoided the possible adverse effect that may arise out of use of urokinase as well as made the procedure cost-effective by reducing the use of additional device with equally effective outcome. To the best of our knowledge, this is first such report from the subcontinent.
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Nil. Her activated partial thromboplastin time and prothrombin time at the emergency was within normal range; thrombin time and anti-factor Xa activity assays were not available. She was given intravenous thrombolysis after discussing the risks with the available family member and caretaker. Tissue plasminogen activator was started by 200 min from onset with a door to needle time of 50 min. NIHSS score dropped 8 points in 2 h with improvement in motor scores. A repeat CT brain showed disappearance of the hyperdense MCA with a left frontotemporal infarct [ Figure 1b ]. The patient was started on aspirin after the 24 h CT scan which showed no evidence of bleeding. Mild word finding issues persisted. She was discharged after 5 days with low-dose apixaban which was later changed to full dose after a repeat CT taken at day 14. She was counseled well regarding the dose and schedule of apixaban and is under follow-up with no deficits.
As more patients are on newer oral anticoagulants (NOACs) for secondary prevention, identification of the right candidate for intravenous thrombolysis can be a challenge. Although guidelines suggest mechanical thrombectomy as the primary treatment and do not warrant intravenous thrombolysis for patients on NOACs, inadequate endovascular facilities make intravenous thrombolysis relevant. The emergency facilities to do anti-factor Xa activity, thrombin time, or ecarin clotting time are not available in most of the centers. Routine coagulation tests will not predict the accurate biological activity of the NOACs. [1] However, a normal baseline coagulation profile can rule out a major overdosage. Of the NOACs, apixaban has a bleeding risk comparable to aspirin. [2] Animal studies in rats showed less hemorrhagic transformation of infarct in rivaroxaban or apixaban pretreated rats compared to warfarin pretreated rats due to the reduced matrix metalloproteinase (MMP-9) expression by the anti-factor Xa inhibitors. [3] Another multicenter observational cohort study reported that the patients on NOACs who underwent revascularization with intravenous thrombolysis for an acute ischemic stroke have a safety profile compared to when used in patients on subtherapeutic Vitamin K antagonist treatment or in those not on any anticoagulation. [4] This case adds to this point that apixaban-treated patients can also be candidates for thrombolysis. A subgroup of patients with low drug levels could be eligible for thrombolysis, but identifying these patients at the emergency setting is difficult. A point of care device for the detection of three NOACs in emergency was feasible in a recent study. [5] Many patients might have missed a single dose and could be exposed to risk of stroke. Significant drug or food interaction of factor Xa inhibitors due to intestinal P glycoprotein (P-gp) inhibition while taking ayurvedic medications containing phytates and 
